FBRX - Forte Biosciences Inc

https://www.fortebiorx.com

Recent News

All You Need to Know About Forte Biosciences ( FBRX ) Rating Upgrade to Buy

Zacks Commentary • 5 months, 1 week ago • score: 0.33

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bullish

Why Forte Biosciences ( FBRX ) Stock Is Trading Lower - Forte Biosciences ( NASDAQ:FBRX )

Benzinga • 8 months, 4 weeks ago • score: 0.32

Forte Biosciences Inc FBRX shares are trading lower by 17.9% to $19.03 Monday afternoon after the company announced it filed for an offer and resale from time to time of up to 9.5 million shares of common stock by selling stockholders.

Bullish

Forte Biosciences Shares Are Soaring Today: What's Going On? - Forte Biosciences ( NASDAQ:FBRX )

Benzinga • 9 months, 3 weeks ago • score: 0.38

Forte Biosciences Inc. FBRX shares are trading higher Wednesday. The company announced a $53 million private placement to fund the development of its autoimmune-focused drug candidate, FB102. Here's what you need to know.

Bullish

Forte Biosciences ( FBRX ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 9 months, 3 weeks ago • score: 0.34

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.

52W High

$28.68

52W Low

$4.11

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.69

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.87

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.42

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.96%

Institutions (25–75% balanced)

82.02%

Shares Outstanding

12,432,900

Float

10,222,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-3.68

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.74%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—